Indian contract research and manufacturing company Kemwell Biopharma has acquired North Carolina-based CRO Cirrus Pharmaceuticals, which offers development services for inhaled and nasal drugs among other dosage forms. Cirrus also provides analytical services for OINDPs.
Cirrus President Anthony Hickey comented, “This acquisition is a testament to the tremendous value our talented employees have created for Cirrus over the past several years. The acquisition will transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms. The Cirrus team looks forward to joining the Kemwell family and continuing to provide the high customer satisfaction it always has.”
Kemwell Chairman Anurag Bagaria said, “Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company. Cirrus will complement the existing contract services offered by Kemwell with early stage innovative product development. Kemwell will now provide customers with a complete solution from early development in the US to commercial manufacturing in Kemwell’s EMA, FDA and PMDA approved facilities in India and Sweden.”
Kemwell President R&D Ninad Deshpanday added, “With Cirrus’ development capabilities and Kemwell’s manufacturing expertise, we will be able to develop products with faster time-to-clinic and significant cost savings for our customers.”
Read the Kemwell Biopharma press release.
